Literature DB >> 30524704

Clozapine, HIV and neutropenia: a case report.

Eromona Whiskey1, David O'Flynn2, David Taylor3.   

Abstract

There is paucity of information on the use of clozapine in patients with HIV. Ethnicity, co-prescribed medications and possible drug-drug interactions are important considerations in evaluating risk of blood dyscrasias during clozapine treatment. Individuals with HIV should not be denied access to the most effective antipsychotic, but a multidisciplinary approach is essential for optimal outcome in such complex patients.

Entities:  

Keywords:  Clozapine; HIV; anti-retroviral agents; drug interactions; neutropenia

Year:  2018        PMID： 30524704      PMCID： PMC6278747          DOI： 10.1177/2045125318804499

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN： 2045-1253


  18 in total

1.  Clozapine treatment of HIV-associated psychosis--too much bone marrow toxicity?

Authors:  M Dettling; B Müller-Oerlinghausen; P Britsch
Journal:  Pharmacopsychiatry       Date:  1998-07       Impact factor: 5.788

Review 2.  Schizophrenia and HIV.

Authors:  D D Sewell
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

3.  Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study.

Authors:  Alexandra M Levine; Roksana Karim; Wendy Mack; D Jay Gravink; Katherine Anastos; Mary Young; Mardge Cohen; Meg Newman; Michael Augenbraun; Stephen Gange; D Heather Watts
Journal:  Arch Intern Med       Date:  2006-02-27

4.  Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.

Authors:  K Atkin; F Kendall; D Gould; H Freeman; J Liberman; D O'Sullivan
Journal:  Br J Psychiatry       Date:  1996-10       Impact factor: 9.319

5.  The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.

Authors:  Maria Ferrara; Anya Umlauf; Chelsea Sanders; Jonathan M Meyer; John Allen McCutchan; Nichole Duarte; Joseph Hampton Atkinson; Igor Grant; Ronald J Ellis
Journal:  Psychiatry Res       Date:  2014-04-18       Impact factor: 3.222

6.  Use of antipsychotic medications among HIV-infected individuals with schizophrenia.

Authors:  Ann Bagchi; Usha Sambamoorthi; Elizabeth McSpiritt; Philip Yanos; James Walkup; Stephen Crystal
Journal:  Schizophr Res       Date:  2004-12-01       Impact factor: 4.939

7.  Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

Authors:  Catia Marzolini; Sara Gibbons; Saye Khoo; David Back
Journal:  J Antimicrob Chemother       Date:  2016-03-05       Impact factor: 5.790

Review 8.  Haematological manifestations of human immune deficiency virus infection.

Authors:  Prakash Vishnu; David M Aboulafia
Journal:  Br J Haematol       Date:  2015-10-09       Impact factor: 6.998

9.  Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Authors:  J M Alvir; J A Lieberman; A Z Safferman; J L Schwimmer; J A Schaaf
Journal:  N Engl J Med       Date:  1993-07-15       Impact factor: 91.245

Review 10.  Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor: A Systematic Review.

Authors:  John Lally; Steffi Malik; Eromona Whiskey; David M Taylor; Fiona P Gaughran; Amir Krivoy; Robert J Flanagan; Aleksandar Mijovic; James H MacCabe
Journal:  J Clin Psychopharmacol       Date:  2017-08       Impact factor: 3.153
View more
  1 in total

1.  Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.

Authors:  Beatriz Oda Plasencia-García; Gonzalo Rodríguez-Menéndez; María Isabel Rico-Rangel; Ana Rubio-García; Jaime Torelló-Iserte; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.